Lv5
810 积分 2023-06-12 加入
Immunosuppressive Macrophages Limit PARP Inhibitor Efficacy in TNBC
3天前
已关闭
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
3天前
已完结
Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma
7天前
已完结
[177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy
7天前
已完结
Leveraging chemotherapy-induced PD-L1 upregulation to potentiate targeted PD-L1 degradation using nanoparticle-based targeting chimeras
7天前
已完结
Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features
17天前
已完结
Depolymerizable Enzymatic Cascade Nanoreactor for Self‐Enhancing Targeting Synergistic Tumor Therapy
19天前
已完结
Erratum for the Research Article “CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors” by C. Reinshagen et al
19天前
已关闭
Tiragolumab active in PD-L1+ NSCLC
20天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
20天前
已完结
皖公网安备34019202002308
